Literature DB >> 7396388

Somatomedin activity in cystic fibrosis and reserpinized rats: possible explanation for growth retardation.

J A Lee, L S Dickinson, B S Kilgore, R H Warren, M J Elders.   

Abstract

Somatomedin activity in children who have cystic fibrosis is reduced to approximately 50 percent of the levels found in normal children. In contrast, the growth hormone concentration in these patients, both the resting and the stimulated levels, was found to be no different from normal children (17.2 and 18.4 ng per ml, respectively). Reserpinized rats have been proposed as a model for cystic fibrosis. Serum somatomedin activity in rats treated with reserpine (0.50 mg per kg per d x 7 days) was reduced to 30 percent of the levels measured in control rats. Reserpine also decreased radiosulfate incorporation into cartilage glycosaminoglycan (GAGS) in vivo and in vitro. Fasting decreased serum somatomedin activity as well as the concentration of GAGS in rat cartilage. Refeeding for 24 hours restored these parameters to normal. These data suggest that one mechanism for the growth retardation occurring in patients who have cystic fibrosis may be explained by decreased serum somatomedin activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396388

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  5 in total

1.  Head growth in cystic fibrosis following early diagnosis by neonatal screening.

Authors:  S Ghosal; C J Taylor; M Pickering; J McGaw
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 2.  Stunted growth with more or less normal appearance.

Authors:  J R Bierich; H Enders; U Heinrich; R Huenges; M B Ranke; D Schoenberg
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

3.  Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis.

Authors:  A M Taylor; A Bush; A Thomson; P J Oades; J L Marchant; C Bruce-Morgan; J Holly; L Ahmed; D B Dunger
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

4.  Diminished concentrations of insulin-like growth factor I in cystic fibrosis.

Authors:  E M Laursen; A Juul; S Lanng; N Høiby; C Koch; J Müller; N E Skakkebaek
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

5.  Growth failure and treatment in cystic fibrosis.

Authors:  Trang N Le; Abeer Anabtawi; Melissa S Putman; Vin Tangpricha; Michael S Stalvey
Journal:  J Cyst Fibros       Date:  2019-10       Impact factor: 5.482

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.